|
|
Am. J. Biomed. Sci. 2013, 5(3), 177-187; doi: 10.5099/aj130300177 |
Genetic Polymorphism of Cytochrome P450 2C9 (CYP2C9) in
Two Ethnic Groups in Iran |
Ogholdondy Agh Ataby,
Robabeh Ghiyas Tabari, Azad Reza Mansourian,
Nader Mansour Samai, Abdoljalal Marjani* |
Department of Biochemistry and Biophysics, Metabolic
Disorders Research Center, Gorgan Faculty of
Medicine, Golestan University of Medical Sciences, Gorgan, Golestan province, Iran. |
*Corresponding
author: |
Abdoljalal Marjani |
Department of Biochemistry and Biophysics |
Metabolic Disorders Research Center |
Gorgan Faculty
of Medicine |
Golestan
University of Medical Sciences |
Gorgan, Golestan province |
Iran |
Tel: +98(171)4421651 |
Fax: +98(171) 4440225 |
E-mail:
abdoljalal@yahoo.com |
Abstract Cytochrome P450 2C9 is considered as a vital enzyme for drugs and toxic detoxification in human body. The present study was carried out to assess the distribution of CYP2C9 allele and genotypic variants in two ethnic groups (Fars and Turkman) in the North East of Iran. The present study contained 110 unrelated healthy Turkman origin and 110 unrelated healthy Fars origin people who were referred to the Health Center. CYP2C9 genotyping were done by Polymerase Chain Reaction (PCR)-Restriction Fragment Length Polymorphism (RFLP) technique. The allele frequency of CYP2C9*1, CYP2C9*2 and CYP2C9*3 in Turkman ethnic group were 88%, 8% and 4%, respectively. The frequency of above alleles in Fars ethnic group was 83%, 11% and 6%, respectively. 15.45%, 7.27%, 0%, 0.9 and 0% Turkman ethnic group belong to CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, respectively. 76.36% and 70% of Turkman and Fars ehtnic groups were with CYP2C9*1/*1 genotype, respectively. 14.55%, 10.91%, 2.73%, 1.83% and 0% of Fars ethnic group was with CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3 genotypes, respectively. There were no significant differences in allele and genotype frequencies between two (Turkman and Fars) ethnic groups (P>0.05).It is demonstrated that there is a significant CYP2C9 alleles and genotypes difference among the worldwide populations based on the collective data from published work and our results. These differences might cause variations in drug dose necessities. These findings may help clinicians to make a choice and suitable plan for the optimal dosage of some drugs and reduce drugs side effects and intoxification. Keywords:
CYP2C9 polymorphism,
Iranian Turkman and
Fars ethnic groups, polymerase chain reaction–restriction fragment
length polymorphism (PCR-RFLP). Download the full article (PDF)
|
Publisher | Missions and Scope | Editorial Board | Instructions for Authors |
© American Journal of Biomedical Sciences 2007-2021. All Rights Reserved. |